文档介绍：（优选）他汀药物临床应用指南
第一页，共五十二页。
冠心病的分型
急性冠脉综合症（ACS）
不稳定型心绞痛（UA）
非ST段抬高性心肌梗死（NSTEMI）
ST段抬高性心肌梗死（STEMI）
冠心病猝死
慢性冠心病
稳定型心绞l／L(80 mg／dn)以下 (证据水平A)。
中华心血管病杂志2007年4月第35卷第4期
？
第十一页，共五十二页。
2007 ACC AHA for UA and NSEMI
第十二页，共五十二页。
There is a wealth of evidence that cholesterol-lowering therapy for patients with CAD and hypercholesterolemia or with mild cholesterol elevation (mean 209 to 218 mg per dL) after MI and UA reduces vascular events and death. Moreover, recent trials have provided mounting evidence that statin therapy is beneficial regardless of whether the baseline LDL-C level is elevated. More aggressive therapy has resulted in suppression or reversal of coronary atherosclerosis progression and lower cardiovascular event rates, although the impact on total mortality remains to be clearly established. These data are discussed more fully elsewhere.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction。Journal of the American College of Cardiology Vol. 50, No. 7, 2007。
第十三页，共五十二页。
急性ST段抬高型心肌梗死诊断和治疗指南
中华心血管病杂志2010年8月第38卷第8期
第十四页，共五十二页。
冠状动脉及其他动脉硬化性血管病二级预防指南-2006 AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease
第十五页，共五十二页。
Furthermore, if it is not possible to attain LDL-C 70 mg/dL because of a high baseline LDL-C, it generally is possible to achieve LDL-C reductions of 50% with either statins or LDL-C –lowering drug combinations.
---- LDL-C<70mg/dl 或降幅50%
Moreover, this guideline for patients with atherosclerotic disease does not modify the recommendations of the 2004 ATP III update for patients without atherosclerotic disease who have diabetes or multiple risk factors and a 10-year risk level for CHD 20%. In the latter 2 types of high-risk patients, the recommended LDL-C goal of 100mg/dL has not changed.
2006 AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular